Drug
Ocrelizumab clinical trials
Also written Ocrevus and RO4964913.
- studies test it
- 56
- open now
- 6
- in phase 3
- 30
- first study started
- 2004
Keep track of what changes. Save the ocrelizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
56 studies that test it; most in 2022 (7)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 1 |
| 2011 | 3 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 5 |
| 2020 | 6 |
| 2021 | 3 |
| 2022 | 7 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 10
- Phase 3
- 30
- Phase 4
- 15
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 41 · Other 15
Hoffmann-La Roche (22) · Genentech, Inc. (13) · University of California, San Francisco (2) · Johns Hopkins University (2) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Fondation Ophtalmologique Adolphe de Rothschild (1) · R-Pharm (1) · Georgia State University (1)
Often tested with
Tested in the same studies.
Allogeneic Natural Killer Cells IDP-023 (1) · Siponimod (1) · Methotrexate (1)
Studies
Open first, then newest update. How each study uses ocrelizumab is read from its arms, and is right about nine times in ten.
Testing it · 56
- A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 TherapyRecruitingPhase 4Genentech, Inc.NCT07609719Written as OCR SC
- Ocrelizumab for Psychosis by AutoimmunityRecruitingPhase 1/2The Methodist Hospital Research InstituteNCT03971487Written as Ocrelizumab infusion
- Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple SclerosisEnrolling by invitationPhase 4University of California, San FranciscoNCT06495593Written as Ocrelizumab
- An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab TreatmentRecruitingPhase 3Hoffmann-La RocheNCT06675955Written as Ocrelizumab
- A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple SclerosisRecruitingPhase 3CelltrionNCT05906992Written as CT-P53
- Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714RecruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT03691077Written as Ocrelizumab
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple SclerosisActive, not recruitingPhase 4Hoffmann-La RocheNCT07483450Written as Ocrelizumab
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)Active, not recruitingPhase 3Hoffmann-La RocheNCT04544436Written as Ocrelizumab
- This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)CompletedPhase 3Hoffmann-La RocheNCT03599245Written as Ocrelizumab
- A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple SclerosisActive, not recruitingPhase 2Hoffmann-La RocheNCT04075266Written as Ocrelizumab
- Ocrelizumab Discontinuation in Relapsing Multiple SclerosisActive, not recruitingPhase 4National Institute of Allergy and Infectious Diseases (NIAID)NCT05285891Written as Ocrelizumab
- Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority TrialActive, not recruitingPhase 3Fondation Ophtalmologique Adolphe de RothschildNCT05999604Written as Ocrelizumab Injection [Ocrevus]
- A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple SclerosisCompletedPhase 3Hoffmann-La RocheNCT05232825Written as Ocrelizumab IV
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple SclerosisActive, not recruitingPhase 3Hoffmann-La RocheNCT05269004Written as Ocrelizumab
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)Active, not recruitingPhase 3Hoffmann-La RocheNCT04548999Written as Ocrelizumab
- A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple SclerosisActive, not recruitingPhase 3Hoffmann-La RocheNCT03523858Written as Ocrelizumab
- A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)Active, not recruitingPhase 3Hoffmann-La RocheNCT05123703Written as Ocrelizumab
- A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With ExacerbationsActive, not recruitingPhase 1R-PharmNCT07597668Written as RPH-035
- Effects of Ocrevus in Relapsing Multiple SclerosisActive, not recruitingPhase 4Georgia State UniversityNCT04387734Written as Ocrelizumab
- B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple SclerosisActive, not recruitingPhase 4Amsterdam UMC, location VUmcNCT05296161Written as Ocrelizumab
See all 56 studies that test ocrelizumab →
Given in every arm · 3 — ocrelizumab is usual care beside what is tested
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)RecruitingPhase 2Hoffmann-La RocheNCT07282574Written as Ocrelizumab
- A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)Active, not recruitingPhase 2Hoffmann-La RocheNCT07074886Written as Ocrelizumab Test Formulation
- A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple SclerosisCompletedPhase 1Hoffmann-La RocheNCT03972306Written as Ocrelizumab
As the comparator · 10 — what is tested is compared with ocrelizumab
- Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.RecruitingPhase 3Novartis PharmaceuticalsNCT06846281Written as Ocrelizumab
- Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple SclerosisRecruitingPhase 4Johns Hopkins UniversityNCT07389590Written as Ocrelizumab
- A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple SclerosisRecruitingPhase 3BiocadNCT07321093Written as Ocrelizumab
- A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)Active, not recruitingPhase 2Hoffmann-La RocheNCT07074886Written as Ocrelizumab Test Formulation
- Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)Active, not recruitingPhase 3AmgenNCT06700343Written as Ocrelizumab (US)
- A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple SclerosisActive, not recruitingPhase 3Hoffmann-La RocheNCT04544449Written as Ocrelizumab
- Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple SclerosisActive, not recruitingPhase 3Rigshospitalet, DenmarkNCT04688788Written as Ocrelizumab
- Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS DiseaseActive, not recruitingPhase 3Haukeland University HospitalNCT04578639Written as Ocrelizumab
- Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)Active, not recruitingPhase 3Haukeland University HospitalNCT03477500Written as Ocrelizumab
- Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled TrialTerminatedPhase 2Universitätsklinikum Hamburg-EppendorfNCT04971005Written as Ocrelizumab
Codes
What other systems call ocrelizumab · ClinicalTrials.gg INT005359
- MeSH (NLM) C533411ocrelizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) A10SJL62JYOCRELIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1876366Confirmed FDA, Wikidata
- Wikidata Q2013780ocrelizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66250OcrelizumabOne source FDA
- DrugBank DB11988One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C533411 | ocrelizumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | A10SJL62JY | OCRELIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1876366 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2013780 | ocrelizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66250 | Ocrelizumab | One source FDA |
| DrugBank | DB11988 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.